In addition, heat-stable oxytocin as a SL FDT offers the favorable side effect profile of the WHO uterotonic drug of choice with the added advantage of being indicated potentially for both prevention and management of PPH. This evidence concerns the gene OXT and pulmonary arterial hypertension.